Hexagon to scale up fungal metabolite discovery for new therapeutic compounds with $47M series A

With a focus on fungal infections and cancer, Hexagon is sourcing secondary metabolites from fungal genomes to develop small molecules against new protein targets. 

Hexagon Bio Inc. announced Tuesday that it has raised $47 million in a series A round led by The Column Group and has hired Tod Smeal as CSO. Smeal was CSO of cancer biology and oncology drug discovery at the Lilly Research Labs division of Eli Lilly and Co. (NYSE:LLY)...